Ro60-0175
| Clinical data | |
|---|---|
| Other names | (S)-5,6-Difluoroindolmethylethylamine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.189.524 |
| Chemical and physical data | |
| Formula | C11H12ClFN2 |
| Molar mass | 226.68 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ro60-0175, also known as (S)-5,6-difluoroindolmethylethylamine, is a serotonin receptor agonist of the isotryptamine group developed by Hoffmann–La Roche, which has applications in scientific research.
It acts as a potent and selective agonist of both the serotonin 5-HT2B and 5-HT2C receptor subtypes, with good selectivity over the closely related serotonin 5-HT2A subtype, and little or no affinity at other receptors. However, Ro60-0175 also activates the serotonin 5-HT2A receptor less potently than the serotonin 5-HT2B and 5-HT2C receptors.
In combination with the selective serotonin 5-HT2C receptor antagonist SB-242084, Ro60-0175 robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. This effect is abolished by addition of the selective serotonin 5-HT2A receptor antagonist ketanserin or volinanserin. The preceding findings suggest that Ro60-0175 may be a serotonergic psychedelic and may have hallucinogenic effects in humans at sufficiently high doses.